Analysis of Inclisiran in the US FDA Adverse Event Reporting System (FAERS): a focus on overall patient population and sex-specific subgroups

被引:2
作者
He, YuBin [1 ]
Guan, Xin [1 ]
Zhang, YaYun [1 ]
Zhu, Zixiong [1 ]
Zhang, YanHui [1 ]
Feng, Yue [1 ]
Li, Xuewen [1 ]
机构
[1] Shanxi Med Univ, Shanxi Bethune Hosp, Tongji Shanxi Hosp, Hosp 3,Shanxi Acad Med Sci,Dept Cardiovasc Med, 99 Longcheng St, Taiyuan 030032, Peoples R China
基金
中国国家自然科学基金;
关键词
Inclisiran; real-world data analysis; adverse event; overall patient population; sex-specific subgroups; RISK; SAFETY; PCSK9;
D O I
10.1080/14740338.2024.2348562
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BackgroundOur study aimed to identify inclisiran-related adverse events(AEs) for primary hypercholesterolemia and arteriosclerotic cardiovascular disease(ASCVD) from the US FDA Adverse Event Reporting System (FAERS) database, analyzing its links to AEs in the overall patient population and sex-specific subgroups to improve medication safety.MethodsWe analyzed inclisiran-related AEs signals by using statistical methods like Reporting Odds Ratio (ROR), Proportional Reporting Ratios (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma-Poisson Shrinker (MGPS).ResultsAnalyzing 2,400 AE reports with inclisiran as the primary suspected drug in the FAERS database, we identified 70 AE signals over 13 organ systems using the above four methods. Notable findings were strong signals for systemic diseases and various reactions at the site of administration (ROR 1.49, 95% CI 1.41-1.57), and various musculoskeletal and connective tissue diseases (ROR 4.07, 95% CI 3.83-4.03) in overall and gender-specific populations. Myalgia, a new ADE signal not in the drug insert, was a top signal by intensity and frequency (ROR 14.76, 95% CI 12.84-16.98).ConclusionOur study revealed the strongest AE signals associated with inclisiran in both the overall population and gender subgroups, highlighting potential risks in clinical medication use and guiding balanced clinical decision-making.
引用
收藏
页码:1561 / 1569
页数:9
相关论文
共 25 条
[2]   Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel [J].
Boren, Jan ;
Chapman, M. John ;
Krauss, Ronald M. ;
Packard, Chris J. ;
Bentzon, Jacob F. ;
Binder, Christoph J. ;
Daemen, Mat J. ;
Demer, Linda L. ;
Hegele, Robert A. ;
Nicholls, Stephen J. ;
Nordestgaard, Brge G. ;
Watts, Gerald F. ;
Bruckert, Eric ;
Fazio, Sergio ;
Ference, Brian A. ;
Graham, Ian ;
Horton, Jay D. ;
Landmesser, Ulf ;
Laufs, Ulrich ;
Masana, Luis ;
Pasterkamp, Gerard ;
Raal, Frederick J. ;
Ray, Kausik K. ;
Schunkert, Heribert ;
Taskinen, Marja-Riitta ;
van de Sluis, Bart ;
Wiklund, Olov ;
Tokgozoglu, Lale ;
Catapano, Alberico L. ;
Ginsberg, Henry N. .
EUROPEAN HEART JOURNAL, 2020, 41 (24) :2313-+
[3]   Using MedDRA - Implications for risk management [J].
Brown, EG .
DRUG SAFETY, 2004, 27 (08) :591-602
[4]   Pro-resolving lipid mediators as therapeutic leads for cardiovascular diseases [J].
Cheng, Yuanyuan ;
Rong, Jianhui .
EXPERT OPINION ON THERAPEUTIC TARGETS, 2019, 23 (05) :423-436
[5]   Statins and the Risk of Diabetes: Evidence From a Large Population-Based Cohort Study [J].
Corrao, Giovanni ;
Ibrahim, Buthaina ;
Nicotra, Federica ;
Soranna, Davide ;
Merlino, Luca ;
Catapano, Alberico L. ;
Tragni, Elena ;
Casula, Manuela ;
Grassi, Guido ;
Mancia, Giuseppe .
DIABETES CARE, 2014, 37 (08) :2225-2232
[6]   Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents [J].
Di Pino, Antonino ;
DeFronzo, Ralph A. .
ENDOCRINE REVIEWS, 2019, 40 (06) :1447-1467
[7]   Inclisiran-New hope in the management of lipid disorders? [J].
Dyrbus, Krzysztof ;
Gasior, Mariusz ;
Penson, Peter ;
Ray, Kausik K. ;
Banach, Maciej .
JOURNAL OF CLINICAL LIPIDOLOGY, 2020, 14 (01) :16-27
[8]   Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel [J].
Ference, Brian A. ;
Ginsberg, Henry N. ;
Graham, Ian ;
Ray, Kausik K. ;
Packard, Chris J. ;
Bruckert, Eric ;
Hegele, Robert A. ;
Krauss, Ronald M. ;
Raal, Frederick J. ;
Schunkert, Heribert ;
Watts, Gerald F. ;
Boren, Jan ;
Fazio, Sergio ;
Horton, Jay D. ;
Masana, Luis ;
Nicholls, Stephen J. ;
Nordestgaard, Borge G. ;
van de Sluis, Bart ;
Taskinen, Marja-Riitta ;
Tokgozoglu, Lale ;
Landmesser, Ulf ;
Laufs, Ulrich ;
Wiklund, Olov ;
Stock, Jane K. ;
Chapman, M. John ;
Catapano, Alberico L. .
EUROPEAN HEART JOURNAL, 2017, 38 (32) :2459-2472
[9]   Small Interfering RNA Therapeutic Inclisiran: A New Approach to Targeting PCSK9 [J].
German, Charles A. ;
Shapiro, Michael D. .
BIODRUGS, 2020, 34 (01) :1-9
[10]   Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9-A Narrative Review [J].
Mercep, Iveta ;
Friscic, Nikolina ;
Strikic, Dominik ;
Reiner, Zeljko .
CARDIOVASCULAR THERAPEUTICS, 2022, 2022